Roger Stupp, MD
Professor, Neurological Surgery; Feinberg School of Medicine
After completion of my clinical training in oncology/hematology,I have devoted my career to innovative treatments of cancer, with a special focus on brain tumors. While single modality treatment approaches may not suffice to demonstrate meaningful improvement in outcome in heterogeneous and molecularly complex solid tumors, my focus has been on combination treatments and association of various treatment modalities.Understanding of pathogenesis and biology will enable substantial treatment advances, thus my dedication has been on translation not only form the lab to the bedside, but also from the clinic back to the bench. Jointly with my colleagues in basic, translational, and clinical research I have been involved with the development of several novel treatments for glioblastoma. Most notably, our close interdisciplinary interaction allowed for establishing two new FDA-approved treatments for glioblastoma that remain the worldwide standard of care. From 2012 until 2017, I have served as the president of the European Organisation for Research and Treatment of Cancer (EORTC), the only pan-European Cooperative Group in Cancer. I have also contributed to consortia such as the National Cancer Institute of Canada (NCIC) Clinical Trials Group and NRG Oncology (formerly RTOG), among others.I bring particular expertise in trial design and conduct, integration of innovative therapies in daily clinical practice and translation of laboratory findings to meaningful improvement in therapeutic strategies, as well as bringing clinical observations back to the bench.